Role of Dexmedetomidine as Synergistic Agent

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE2/PHASE3

Total Enrollment

166 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-11-30

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this clinical trial is to contribute valuable insights into the role of Dexmedetomidine as a synergistic agent in prolonging subarachnoid block duration, with the overarching goal of enhancing perioperative care and surgical success rates.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Prolonging Effect of Dexmedetomidine on Spinal Anesthesia Through Different Routes if Administrations

NCT06769737

Spinal Anesthesia Evaluation

NOT_YET_RECRUITING PHASE4

Effect of Dexmedetomidine on Hemodynamic Response to Endotracheal Intubation in Hypertensive Patients

NCT06712186

Elective Surgical Patient Hypertensive Patients Blood Pressure +2 more

RECRUITING PHASE1/PHASE2

Comparision of Different Doses of Dexmedetomidine With Low Dose Bupivacaine in Selective Spinal Anesthesia.

NCT04037774

Drug Effect

UNKNOWN PHASE4

Comparison of Efficacy of Bupivacaine in Supraclavicular Block With or Without Dexmedetomidine

NCT05991375

Pain

COMPLETED PHASE4

Comparative Analysis of Intraoperative Effect Dexmedetomidine and Fentanyl as an Adjuvant to Heavy Bupivacaine in Spinal Anaesthesia in Lower Limb Orthopedic Surgeries to Evaluate the Hemodynamic Stability and Onset and Duration of Motor Block of Using Intrathecal Dexmedetomidine and Fentanyl

NCT07078201

Spinal Anesthesia Duration

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Dexmedetomidine is a frequently used alpha-2 adrenergic agonist for anesthesia and sedation due to its excellent selectivity. Dexmedetomidine can cause drowsiness, analgesia, and sympathetic reactions when injected intravenously. Dexmedetomidine has been investigated for possible synergistic benefits when used in conjunction with hyperbaric bupivacaine for subarachnoid block, sometimes referred to as spinal anesthesia. Because hyperbaric bupivacaine can produce a rapid onset and a longer duration of sensory and motor blockage, it is a common local anesthetic used in spinal anesthesia.

Numerous research studies have examined the synergistic effects of intravenous dexmedetomidine and hyperbaric bupivacaine in subarachnoid blocks. These effects are primarily observed in terms of extending the duration of sensory and motor blockade, enhancing postoperative analgesia, decreasing intraoperative and postoperative opioid consumption, and improving patient satisfaction. The mechanism underlying this synergistic effect is believed to be connected to the effects of dexmedetomidine on the central nervous system, which include its capacity to modify pain pathways, improve spinal anesthesia, and produce drowsiness and anxiolysis.

Although the combination of dexmedetomidine with hyperbaric bupivacaine has demonstrated encouraging outcomes in a number of studies, there is still discussion and continuing research over the best time, dosage, and patient selection criteria. As with any anesthesia procedure, the best course of action should be determined after taking into account specific patient considerations such age, comorbidities, and concurrent drugs.

Hameed et al compare the Synergistic effect of Dexmedetomidine on Subarachnoid Block with Hyperbaric Bupivacaine among three groups. In there study Patients in Group 1 received 2 ml of intrathecal bupivacaine; Group 2 received a combination of bupivacaine and Dexmedetomidine infusion; and Group 3 received bupivacaine followed by Dexmedetomidine infusion. Their study show that onset time of sensory blockade. The duration of sensory blockade and the rate of recovery of complete sensory block was significantly higher in Group 2 compared to Group 1. The distribution of adverse effect among group 1 and group 2 was, hypotension 20% vs 40%, Bradycadria 8% vs 24%, and Nausea 12% vs 12% respectively.

Previous studies have indicated that Dexmedetomidine can enhance the duration and quality of sensory blockade, improve postoperative analgesia, and reduce opioid consumption when used in conjunction with hyperbaric bupivacaine. Despite these promising findings, further exploration is warranted to elucidate the optimal dosage, timing, and patient selection criteria for Dexmedetomidine administration in subarachnoid blocks. Understanding the mechanistic basis of Dexmedetomidine's synergistic effects on subarachnoid block duration is crucial for refining anesthesia protocols and ultimately improving patient outcomes. By conducting this research study, the investigators aim to contribute valuable insights into the role of Dexmedetomidine as a synergistic agent in prolonging subarachnoid block duration, with the overarching goal of enhancing perioperative care and surgical success rates.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dexmedetomidine Hyperbaric Bupivacaine Subarachnoid Anesthesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A Hyperbaric Bupivicaine

Group A (Unexposed) will received 2 ml of intrathecal bupivacaine.

Group Type EXPERIMENTAL

Hyperbaric bupivacaine

Intervention Type DRUG

Group A (Unexposed) will received 2 ml of intrathecal bupivacaine

GROUP B Hyperbaric Bupivacaine and Dexmedetomidine

Group B (Exposed) will receive a combination of bupivacaine and Dexmedetomidine infusion.

Group Type EXPERIMENTAL

hyperbaric bupivacaine and dexmedetomidine

Intervention Type DRUG

Group B (Exposed) will receive a combination of bupivacaine and Dexmedetomidine infusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hyperbaric bupivacaine

Group A (Unexposed) will received 2 ml of intrathecal bupivacaine

Intervention Type DRUG

hyperbaric bupivacaine and dexmedetomidine

Group B (Exposed) will receive a combination of bupivacaine and Dexmedetomidine infusion

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients of either gender aged between 18 and 65 years.
2. Patients scheduled for surgical procedures of lower limb requiring subarachnoid anesthesia.
3. American Society of Anesthesiologists (ASA) physical status classification I or II.

Exclusion Criteria

1. Patients with contraindications to subarachnoid anesthesia, including severe coagulopathy, infection at the site of injection, or increased intracranial pressure.
2. Patients with a history of significant cardiac, respiratory, hepatic, or renal disease.
3. Pregnant or lactating women.
4. Patients with a history of substance abuse or dependence.
5. Patients on chronic opioid therapy or with opioid tolerance.
6. Patients with neurological deficits affecting sensation or motor function in the lower extremities.
7. Patients with psychiatric disorders affecting their ability to cooperate during the procedure or follow instructions.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No